Research
Hormonal
Plasma GLP-1 and PYY responses do not differ between individuals with obesity and lean controls.
This suggests that obesity does not affect the immediate hormonal response of GLP-1 and PYY to a meal.
StrongRefutesmedium confidence
Plasma GLP-1 and PYY responses did not differ between individuals with obesity and lean controls.
Why this rating
Based on the prospective single-center study design.
Source
Peptide YY and Glucagon-like Peptide-1 Secretion in Obesity
Jennifer Wilbrink et al. · Gastrointestinal Disorders · 2024
DOI 10.3390/gidisord7010003
cohort · n=24Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →